Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Variable Outcome of Allogeneic Stem Cell Transplant According to the Different Levels of Pre-Transplant Minimal Residual Disease, in Adult Patients with Acute Myeloid Leukemia

Francesco Buccisano, MD, Luca Maurillo, MD, Alfonso Piciocchi, Maria Ilaria Del Principe, MD, Gottardo De Angelis, MD, Ambra Di Veroli, MD, Raffaella Cerretti, MD, Mariagiovanna Cefalo, MD, Concetta Ditto, MD, Alessandra Picardi, MD, Laura Cudillo, MD, Benedetta Mariotti, MD, Francesco Lo Coco, MD, William Arcese, MD, Sergio Amadori, MD, Adriano Venditti, MD

Blood (2015) 126 (23): 3230.

https://doi.org/10.1182/blood.V126.23.3230.3230

Published: 2015

Journal Articles

Allogeneic but Not Autologous Stem Cell Transplant Attenuates the Negative Prognostic Impact Dictated By Pretransplant MRD Positivity

Francesco Buccisano, MD, Luca Maurillo, MD, Maria Ilaria Del Principe, Gottardo De Angelis, MD, Raffaella Cerretti, MD, Concetta Ditto, MD, Ambra Di Veroli, MD, Alessandra Picardi, MD, Laura Cudillo, MD, Mariagiovanna Cefalo, MD, Chiara Sarlo, MD, Giorgia Fedele, MD, Marco Refrigeri, MD, Francesco Lo Coco, MD, William Arcese, MD, Sergio Amadori, Adriano Venditti

Blood (2014) 124 (21): 2363.

https://doi.org/10.1182/blood.V124.21.2363.2363

Published: 2014

Journal Articles

Age-Stratified Analysis Of The Prognostic Role Of Minimal Residual Disease Detection By Flow Cytometry, In Adult Patients With Acute Myeloid Leukemia

Francesco Buccisano, MD, Luca Maurillo, MD, Alfonso Piciocchi, PhD, Maria Ilaria Del Principe, MD, Chiara Sarlo, MD, Mariagiovanna Cefalo, MD, Concetta Ditto, MD, Ambra Di Veroli, MD, Daniela Nasso, MD, Marco Refrigeri, MD, Maria Antonietta Irno Consalvo, PhD, Daniela Fraboni, PhD, Consuelo Conti, Giovanni Del Poeta, MD, Francesco Lo Coco, MD, Sergio Amadori, Adriano Venditti, MD

Blood (2013) 122 (21): 2649.

https://doi.org/10.1182/blood.V122.21.2649.2649

Published: 2013

Journal Articles

MRD-Directed Post-Remissional Therapy Dramatically Improves Outcome of Adult Patients with High Risk AML by Implementing Allogeneic Transplant Option

Blood (2010) 116 (21): 2702.

https://doi.org/10.1182/blood.V116.21.2702.2702

Published: 2010

Journal Articles

Phase II Study of Bortezomib as a Single Agent In Patients with Relapsed/Refractory or De Novo Acute Myeloid Leukemia Unfit for Intensive Therapy

Chiara Sarlo, Maria Giovanna Cefalo, Eleonora Ceresoli, Licia Ottaviani, Selenia Campagna, Concetta Ditto, Luigi Di Caprio, Maria Ilaria Del Principe, Annibale Franchi, Luca Maurillo, MD, Francesco Buccisano, MD, Sergio Amadori, Adriano Venditti, MD

Blood (2010) 116 (21): 4360.

https://doi.org/10.1182/blood.V116.21.4360.4360

Published: 2010

NARROW

Variable Outcome of Allogeneic Stem Cell Transplant According to the Different Levels of Pre-Transplant Minimal Residual Disease, in Adult Patients with Acute Myeloid Leukemia

Allogeneic but Not Autologous Stem Cell Transplant Attenuates the Negative Prognostic Impact Dictated By Pretransplant MRD Positivity

Age-Stratified Analysis Of The Prognostic Role Of Minimal Residual Disease Detection By Flow Cytometry, In Adult Patients With Acute Myeloid Leukemia

MRD-Directed Post-Remissional Therapy Dramatically Improves Outcome of Adult Patients with High Risk AML by Implementing Allogeneic Transplant Option

Phase II Study of Bortezomib as a Single Agent In Patients with Relapsed/Refractory or De Novo Acute Myeloid Leukemia Unfit for Intensive Therapy

Email alerts

ASH Publications

American Society of Hematology

Variable Outcome of Allogeneic Stem Cell Transplant According to the Different Levels of Pre-Transplant Minimal Residual Disease, in Adult Patients with Acute Myeloid Leukemia

Allogeneic but Not Autologous Stem Cell Transplant Attenuates the Negative Prognostic Impact Dictated By Pretransplant MRD Positivity

Age-Stratified Analysis Of The Prognostic Role Of Minimal Residual Disease Detection By Flow Cytometry, In Adult Patients With Acute Myeloid Leukemia

MRD-Directed Post-Remissional Therapy Dramatically Improves Outcome of Adult Patients with High Risk AML by Implementing Allogeneic Transplant Option

Phase II Study of Bortezomib as a Single Agent In Patients with Relapsed/Refractory or De Novo Acute Myeloid Leukemia Unfit for Intensive Therapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only